Earnings summaries and quarterly performance for CASTLE BIOSCIENCES.
Executive leadership at CASTLE BIOSCIENCES.
Board of directors at CASTLE BIOSCIENCES.
DM
Daniel M. Bradbury
Detailed
Independent Board Chair
EG
Ellen Goldberg
Detailed
Independent Director
GB
G. Bradley Cole
Detailed
Independent Director
KS
Kimberlee S. Caple
Detailed
Independent Director
MD
Miles D. Harrison
Detailed
Independent Director
RC
Rodney Cotton
Detailed
Independent Director
TP
Tiffany P. Olson
Detailed
Independent Director
Research analysts who have asked questions during CASTLE BIOSCIENCES earnings calls.
KM
Kyle Mikson
Canaccord Genuity
4 questions for CSTL
Also covers: AKYA, BDSX, EXAS +12 more
MC
Mason Carrico
Stephens Inc.
4 questions for CSTL
Also covers: AKYA, CDNA, CTKB +13 more
Thomas Flaten
Lake Street Capital Markets
4 questions for CSTL
Also covers: ACHV, AQST, ASRT +13 more
Mark Massaro
BTIG, LLC
3 questions for CSTL
Also covers: ADPT, AKYA, BLLN +19 more
Paul Knight
KeyBanc Capital Markets
3 questions for CSTL
Also covers: A, AZTA, BLFS +13 more
PS
Puneet Souda
Leerink Partners
3 questions for CSTL
Also covers: A, ABCL, BRKR +20 more
SJ
Sung Ji Nam
Scotiabank
3 questions for CSTL
Also covers: ADPT, BDSX, BNGO +9 more
Catherine Schulte
Baird
2 questions for CSTL
Also covers: A, EXAS, MRVI +7 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for CSTL
Also covers: AKYA, BRKR, CYRX +15 more
TP
Thomas Peterson
Robert W. Baird & Co. Incorporated
2 questions for CSTL
Also covers: TECH, TWST
Corey Rosenbaum
Scotiabank
1 question for CSTL
Also covers: ADPT, VCYT
RL
Ricki Levitus
Guggenheim Securities, LLC
1 question for CSTL
Also covers: MYGN
Subbu Nambi
Guggenheim Securities
1 question for CSTL
Also covers: ADPT, BOLD, BRKR +17 more
Vidyun Bais
BTIG
1 question for CSTL
Also covers: AKYA, BNGO, CERS +5 more
Recent press releases and 8-K filings for CSTL.
Castle Biosciences Announces Preliminary Unaudited Q4 and Full-Year 2025 Results
CSTL
Earnings
Guidance Update
Product Launch
- Castle Biosciences expects 2025 total revenue to exceed $340 million, surpassing its previously guided range of $327-335 million.
- Year-end 2025 cash, cash equivalents and marketable investment securities are anticipated to be approximately $300 million.
- Total test reports for the company's core revenue drivers (DecisionDx-Melanoma and TissueCypher) increased 37% in 2025 compared to 2024.
- The company launched AdvanceAD-Tx, a new test for atopic dermatitis, on a limited access basis in November 2025.
Jan 13, 2026, 2:43 PM
Castle Biosciences Announces Strong Preliminary 2025 Financial and Operational Results
CSTL
Earnings
Guidance Update
Product Launch
- Castle Biosciences expects 2025 total revenue to exceed $340 million, surpassing its previous guidance of $327-335 million.
- The company anticipates year-end 2025 cash, cash equivalents, and marketable investment securities to be approximately $300 million.
- Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% in 2025 over 2024 and 42% in Q4 2025 over Q4 2024.
- AdvanceAD-Tx, a new test designed to guide systemic treatment decisions for atopic dermatitis, was launched on a limited access basis in November 2025.
Jan 11, 2026, 9:00 PM
Castle Biosciences Announces Superiority of DecisionDx-UM and PRAME Combination in Uveal Melanoma Prognosis
CSTL
Product Launch
- Castle Biosciences announced new data from a study published in Nature Communications, demonstrating that the combination of its DecisionDx-UM and PRAME tests provides superior predictions of metastasis-free survival and overall survival in uveal melanoma patients compared to NGS-based gene mutation analysis.
- The study, conducted by the Collaborative Ocular Oncology Group (COOG), validated that the combined DecisionDx-UM and PRAME data offers more precise metastatic risk prediction than either test used independently.
- This superior performance is attributed to DecisionDx-UM's ability to measure gene activity from both tumor cells and surrounding immune cells, offering a more comprehensive view of the tumor microenvironment than targeted NGS.
- Castle Biosciences currently offers DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UM Seq tests for uveal melanoma, providing comprehensive molecular insights for risk assessment and treatment planning.
Dec 17, 2025, 12:00 PM
Castle Biosciences' DecisionDx-Melanoma Endorsed by Expert Consensus Panel
CSTL
New Projects/Investments
- Castle Biosciences (CSTL) announced the publication of an independent expert consensus paper titled "31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel," which unanimously endorses the Company’s DecisionDx-Melanoma test.
- The expert panel concluded that DecisionDx-Melanoma should be recognized as a best-practice approach for guiding management decisions in patients with cutaneous melanoma, supporting more personalized care strategies.
- The test provides prognostic information independent of traditional clinicopathologic factors, significantly enhances prognostic precision when integrated with existing staging systems, and is associated with improved melanoma-specific and overall survival for tested patients.
- DecisionDx-Melanoma has been ordered more than 220,000 times since its launch and is supported by over 50 peer-reviewed publications.
Dec 9, 2025, 12:00 PM
Castle Biosciences Reports Q3 2025 Performance and Launches New Dermatology Test
CSTL
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Castle Biosciences reported strong Q3 2025 performance, with combined revenue from its DecisionDx-Melanoma and TissueCypher tests growing 36% year-over-year, matching volume growth. The company achieved 77% adjusted gross margins and ended the quarter with $287 million in cash and cash equivalents.
- The company announced the limited access rollout of Advance ADTX, a new dermatology test designed to guide systemic therapy selection for patients aged 12 or older with moderate to severe atopic dermatitis. This new test targets an estimated 13 million patients in the US marketplace.
- Castle Biosciences' key products address substantial U.S. total addressable markets, including $540 million for DecisionDx-Melanoma (with approximately 30%-31% market penetration by Q3 2025), $820 million for DecisionDx-SCC, and roughly $1 billion for gastroenterology tests like TissueCypher and EsoPredict.
Dec 2, 2025, 6:10 PM
Castle Biosciences Reports Q3 2025 Performance and Launches New Atopic Dermatitis Test
CSTL
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Castle Biosciences reported strong Q3 2025 performance, with its core DecisionDx-Melanoma and TissueCypher tests achieving a combined 36% revenue and volume growth over the prior year. The company concluded the quarter with $287 million in cash, cash equivalents, and marketable investment securities, and a net loss of $0.5 million.
- The company initiated a limited access rollout of AdvanceAD-Tx, a new test designed to guide systemic therapy selection for patients aged 12 or older with moderate to severe atopic dermatitis. This test uses a 487 gene expression profile to identify patient response profiles.
- AdvanceAD-Tx targets a significant market opportunity of approximately 13 million patients in the US with moderate to severe atopic dermatitis. Clinical study results demonstrated that 45% of patients with a JAK inhibitor responder profile achieved EASI-90 (90% clearance) when on a JAK inhibitor, compared to 8.3% on Th2 biologic therapy.
- Market research indicates strong clinician interest in AdvanceAD-Tx, with 78% of interviewed clinicians stating they would "definitely or probably" use the test. This new offering complements existing dermatology tests, such as DecisionDx-Melanoma, which had a $540 million US TAM and 30%-31% market penetration by Q3 2025.
Dec 2, 2025, 6:10 PM
Castle Biosciences Reports Q3 2025 Performance and Launches Advance ADTX Test
CSTL
Earnings
Product Launch
- Castle Biosciences reported strong Q3 2025 performance, with its core DecisionDx-Melanoma and TissueCypher tests achieving 36% revenue and volume growth year-over-year. The company ended the quarter with $287 million in cash and cash equivalents and an adjusted gross margin of 77%.
- The company announced the limited access rollout of Advance ADTX, a new test designed to guide systemic therapy selection for patients with moderate to severe atopic dermatitis, targeting an estimated 13 million U.S. patients aged 12 and older.
- Clinical study results for Advance ADTX demonstrated that 45% of patients with a JAK inhibitor responder profile on a JAK inhibitor achieved EASI-90 and complete clearance, and achieved EASI-90 3.8 times faster compared to those on Th2 targeted therapy.
- Market research indicated significant clinician interest, with 78% stating they would likely use Advance ADTX, leveraging Castle's existing relationships with medical dermatologists.
Dec 2, 2025, 6:10 PM
Castle Biosciences Reports Strong Q3 Performance and Strategic Updates
CSTL
Guidance Update
Product Launch
New Projects/Investments
- Castle Biosciences reported a 36% year-over-year growth in normalized/pro forma revenue and core TissueCypher and Melanoma test volume for Q3, ending the quarter with $288 million - $289 million in cash or cash equivalents.
- The company raised its year-end guidance to $327 million - $335 million and anticipates pro forma revenue growth of 27%-30% for 2025.
- DecisionDx-Melanoma test volume reaccelerated to 12% growth in Q3, and the company plans to submit for FDA authorization early next year, which could potentially impact reimbursement in late 2027, 2029.
- Castle Biosciences recently launched its atopic dermatitis test on a limited basis and entered a collaboration with SciBase to develop a handheld device for predicting atopic dermatitis flares, opening new pipeline opportunities.
- Gross margin is expected to be in the low 70% exiting 2025, with a potential for mid-70s on an adjusted basis in 2026.
Nov 19, 2025, 3:00 PM
Castle Biosciences Reports Strong Q3 Performance and Strategic Product Updates
CSTL
Guidance Update
Product Launch
New Projects/Investments
- Castle Biosciences reported strong Q3 performance with 36% normalized revenue and volume growth, ending the quarter with $288 million - $289 million in cash, and raised its year-end guidance to $327 million - $335 million.
- DecisionDx-Melanoma growth reaccelerated to 12% in Q3, driven by a sales force shift, and the company expects to submit for FDA approval early next year (2026).
- The company is launching a new atopic dermatitis test, targeting 13 million patients with moderate to severe disease, which predicts response to JAK inhibitors with 45-46% achieving EASI-90 in responders.
- Strategic investments include the Previse deal, offering IP for TissueCypher enhancements and a non-endoscopic self-collection device, and a collaboration with CyBase for a handheld device to predict atopic dermatitis flares.
Nov 19, 2025, 3:00 PM
Castle Biosciences Reports Strong Q3 2025 Growth and Raises Full-Year Guidance
CSTL
Guidance Update
Product Launch
New Projects/Investments
- Castle Biosciences reported 36% year-over-year pro forma revenue and volume growth in Q3 2025 and ended the quarter with $288 million to $289 million in cash. The company also raised its year-end guidance by $16 million to a range of $327 million to $335 million.
- The DecisionDx-Melanoma test reaccelerated to 12% growth in Q3 2025 and the company plans to submit for FDA approval early next year following its breakthrough designation.
- The company recently launched its atopic dermatitis test with a limited rollout planned for the next couple of quarters to understand the market and reimbursement pathways.
- Management anticipates adjusted gross margins in the mid-70s for 2026 and expects to exit 2025 with 27%-30% pro forma revenue growth.
- Future pipeline developments include enhancing the TissueCypher test with multi-omics, a non-endoscopic self-collection device for Barrett's esophagus (expected material impact by 2028-2029), and a collaboration with CyBase for a handheld device to predict atopic dermatitis flares.
Nov 19, 2025, 3:00 PM
Quarterly earnings call transcripts for CASTLE BIOSCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more